Table of Contents
PK-PD relationships for antiretroviral drugs
PK-PD relationships
PK-PD relationships
Indinavir
Indinavir
Indinavir
Indinavir
Indinavir
Saquinavir
Saquinavir
Saquinavir
Saquinavir
Saquinavir
Nelfinavir
Nelfinavir
Nelfinavir and initial decline HIV-1 RNA
Nelfinavir
Nelfinavir
Nelfinavir
Ritonavir
Ritonavir
Nevirapine
Nevirapine
NVP PK-PD relationship
Efavirenz
Treatment outcome by subset of efavirenz concentration windows in studies 266-003/004/005/021/024
Efavirenz
Variability of exposure
Relevance of exposure
Relevance of exposure
Relevance of exposure
Relevance of exposure
Cmin/IC50 ratios
Cmin/IC50 ratios
From in vitro to in vivo?
IC50 versus EC50
Conclusions (1)
Conclusions (2)
Remarks (1)
Remarks (2)
Acknowledgements
|
Author: Richard Hoetelmans
|